Has the symptom severity inclusion requirement narrowed the definition of major depressive disorder in antidepressant efficacy trials?

详细信息    查看全文

• 作者：Mark Zimmerman ; ^{mzimmerman@lifespan.org} ; Emily Walsh ; Iwona Chelminski ; Kristy Dalrymple
• 关键词：Depression ; Severity ; Hamilton Depression Rating Scale ; Generalizability ; Inclusion criteria ; Antidepressant efficacy trial
• 刊名：Journal of Affective Disorders
• 出版年：2017
• 出版时间：15 March 2017
• 年：2017
• 卷：211
• 期：Complete
• 页码：60-64
• 全文大小：183 K
• 卷排序：211

文摘

Placebo-controlled studies of antidepressants require a minimum level of severity on standardized measures such as the HAMD. The number of DSM-5 MDD symptom criteria met is significantly associated with HAMD scores. Thus, placebo-controlled studies of antidepressants require more DSM-IV/DSM-5 symptom criteria than are required for the diagnosis.